TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 Polaris Group , today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with.
HOUSTON, Aug. 04, 2022 Salarius Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the. | August 4, 2022